IA
OPNT

IFP Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

IFP Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-112
Closed -$2K – 3196
2019
Q3 		$2K Buy
+112
New +$1.56K ﹤0.01% 2754
2019
Q1 		$1K Sell
112
-200
-64% -$2.92K ﹤0.01% 2289
2018
Q4 		$4K Hold
312
– – ﹤0.01% 2977
2018
Q3 		$6K Hold
312
– – ﹤0.01% 3159
2018
Q2 		$4K Hold
312
– – ﹤0.01% 3417
2018
Q1 		$7K Hold
312
– – ﹤0.01% 3030
2017
Q4 		$7K Buy
+312
New +$9.99K ﹤0.01% 3076

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

IFP Advisors's OPNT Position: Q4 2019 in Review

IFP Advisors sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2019, closing a stake of 112 shares — an estimated $2K sold.

IFP Advisors first reported a position in OPNT in Q4 2017 and held it in 7 quarters. The position peaked at $7K in Q1 2018. 28 funds tracked by Wall St. Rank hold OPNT as of Q4 2019.

  • IFP Advisors reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • IFP Advisors sold 112 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $2K.
  • IFP Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
  • IFP Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $7K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on IFP Advisors's 13F filing for Q4 2019, filed 17 Jan 2020.